New Jersey/ Bangalore, India – October 10, 2024 – Marlabs LLC, a digital solutions company, announced today that it has been recognized as a “Rising Star” in the ISG Provider Lens™ study for Specialty Analytics services in Life Sciences and Healthcare. This recognition highlights Marlabs’ expertise in delivering tailored analytics and AI-powered solutions that enable Life Sciences and Healthcare organizations enhance patient outcomes, streamline R&D, and improve operational efficiency.

The ISG Provider Lens™ report, known for identifying companies that demonstrate exceptional growth and innovation, awards the Rising Star title to organizations that are on the path to becoming Leaders in the market. Marlabs’ recognition highlights their proven ability to innovate and deliver solutions tailored to the complex demands of Life sciences and Healthcare, setting it apart in a highly competitive industry.

At the core of Marlabs’ offerings is its Modern Analytics Platform (MAP), a comprehensive data strategy framework that enables the development of custom analytics and AI-driven solutions. These solutions address critical challenges across the entire Life Sciences value chain, from drug discovery and safety monitoring to clinical trials, commercialization, regulatory compliance, and supply chain visibility. By leveraging MAP, Marlabs enables pharmaceutical companies to accelerate their R&D efforts, reduce development costs, and bring safer, more effective treatments to market faster. 

According to Manav Deep Sachdeva, Principal Analyst from ISG, “Marlabs uses a combination of deep domain expertise and AI to drive transformation in accelerating drug discovery, optimizing clinical trials, driving patient outcomes, and improving the supply chain for pharmaceutical and medical device clients. Their tailored approach and innovative use of AI make them a key player in the Life Sciences sector.”

Marlabs is also recognized for its innovative use of AI and predictive analytics in drug development and safety monitoring. By applying advanced AI techniques, Marlabs helps pharmaceutical companies conduct targeted research throughout the drug discovery and development process. One of its key strengths is identifying potential safety risks associated with new drugs and treatments, allowing organizations to make informed decisions that prioritize patient safety while advancing drug discovery efforts.

For more information about Marlabs’ Specialty Analytics services in Life Sciences and Healthcare, click here. 

About Marlabs

Marlabs designs and develops digital solutions with data at the center. We leverage our deep data expertise and cutting-edge technology to empower businesses with actionable insights and achieve improved digital outcomes.

Marlabs’ data-first approach intersects with AI & analytics, digital product engineering, and advisory services to build and scale digital solutions. We work with leading companies around the world to make operations sleeker, keep customers closer, transform data into decisions, boost legacy system performance, and seize novel opportunities in new digital revenue streams.

Marlabs is headquartered in New Jersey, with offices in the US, Germany, Canada, Brazil and India.